CMC Biologics, a clinical and commercial manufacturer of therapeutic proteins, has entered into an agreement with CytoDyn, a Vancouver, Washington-headquartered biotechnology company focused on human immunodeficiency virus (HIV) infection, for the process development and commercial manufacture of CytoDyn’s monoclonal antibody (mAb) candidate.

CytoDyn’s mAb is an experimental drug currently in clinical trials for treating HIV and has been granted fast track designation by the US Food and Drug Administration.

Source: CMC Biologics